Taligen Therapeutics, a company developing therapies that regulate the complement system to treat inflammatory and immune diseases, closed a $10 million tranche of a Series B financing. The initial Series B round was secured in February 2008, and with this tranche, Taligen has closed on $36 million of the original $65 million Series B investment.
“This round of funding demonstrates the significant progress we have made over the last several years related to the development of our proprietary tissue-targeting platform technology and our lead drug candidate, TT30,” says Abbie Celniker, Ph.D., CEO and president of Taligen Therapeutics.
“This investment will allow us to advance TT30 through the early stages of clinical development and to continue to build the rest of our pipeline of novel complement inhibitors.” TT30 is being tested in preclinical studies as a treatment for age-related macular degeneration (AMD) and various autoimmune diseases.
Founded in 2004, Taligen maintains its headquarters in Cambridge, MA. The company’s protein therapeutics are designed to selectively identify, target, and concentrate on inflammatory tissues. Taligen reports that its drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic diseases. Its R&D programs include candidates for diseases such as paroxysmal nocturnal hemoglobinuria, AMD, and organ transplant.